IP Due Diligence und Pharma, |transkript 4-2022 im November – Spezial: “Patente / M&A / Lizenzierung”

Market leaders in the life sciences are interested in acquiring start-ups in order to acquire a new technology as soon as their investment risk can be better foreseen. In order to minimise the associated risks, a precise IP due diligence is required on the acquirer’s side. In this article, Dr Marco Stief tries to summarise the most important issues to consider in the article “IP Due Diligence and Pharma” for Transkript.